| Date | Title | Description |
| 06.05.2025 | Calquence combination approved in EU for 1L MCL | Calquence combination approved in EU for 1L MCL
Tue, May 06, 2025 08:02 CET Report this content
06 May 2025
Calquence plus chemoimmunotherapy approved in the EU
as first and only BTK inhibitor for 1st-line mantle cell lymphoma
Approval base... |
| 28.04.2025 | Lymphoma Research Foundation and Institute for Follicular Lymphoma Innovation (IFLI) Host Landmark Workshop on Follicular Lymphoma Innovation | Lymphoma Research Foundation and IFLI Logos
Lymphoma Research Foundation and Follicular Lymphoma Innovation (IFLI) announce major investment to host 2026 International Scientific Workshop to advance research and innovation in follicular lym... |
| 31.03.2025 | AstraZeneca's Breakthroughs: A New Dawn in Cancer Treatment | In the realm of oncology, AstraZeneca is carving a path through the dense forest of cancer treatment. Two recent approvals highlight this journey: Calquence for mantle cell lymphoma (MCL) and Imfinzi for muscle-invasive bladder cancer (MIBC... |
| 31.03.2025 | Calquence recommended for EU approval in 1L MCL | Calquence recommended for EU approval in 1L MCL
Mon, Mar 31, 2025 08:05 CET Report this content
31 March 2025
Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle c... |
| 02.03.2025 | New Faces in the Fight Against Lymphoma: A Commitment to Change | The Lymphoma Research Foundation (LRF) is stepping up its game. Recently, two new members joined its Board of Directors: Ellen M. Walker and Whitney Neighbors. Both women bring unique perspectives and experiences to the table. Their stories... |
| 27.02.2025 | Lymphoma Research Foundation Elects Whitney Neighbors to Board of Directors | Whitney Neighbors
Lymphoma Survivor, Research Advocate, and Prominent Chief Trust Officer Joins Lymphoma Research Foundation Leadership
NEW YORK, Feb. 27, 2025 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation – the nation's largest no... |
| 27.02.2025 | Lymphoma Research Foundation Elects Ellen M. Walker to Board of Directors | Ellen M. Walker
Prominent Attorney and Founder of the Paul Foundation Joins Lymphoma Research Foundation Leadership
NEW YORK, Feb. 27, 2025 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation – the nation's largest non-profit organizatio... |
| 17.01.2025 | Calquence combination approved in US for 1L MCL | Calquence combination approved in US for 1L MCL
Fri, Jan 17, 2025 08:00 CET Report this content
17 January 2025
Calquence plus chemoimmunotherapy approved in the US for
patients with previously untreated mantle cell lymphoma
Based on ECHO P... |
| 13.09.2024 | Breaking Barriers: The Fight Against Lymphoma and Bladder Cancer | In the realm of cancer awareness, two significant events recently unfolded, shining a light on the emotional and physical battles faced by patients. On one hand, World Lymphoma Awareness Day (WLAD) took center stage, while on the other, a g... |
| 13.09.2024 | BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk | SINGAPORE, Sept. 13, 2024 /PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is proud to join the global community in raising awareness about lymphoma on World Lymphoma Awareness Day (WLAD). L... |
| 06.08.2024 | Lymphoma Research Foundation to Honor Longtime Foundation Supporter and Past Board Chair Steven J. Prince at Annual Gala on September 25 | Lymphoma Research Foundation Logo
BeiGene will be presented with the Lymphoma Research Foundation's Corporate Leadership Award for excellence in development of next-generation cancer treatments
NEW YORK, Aug. 6, 2024 /PRNewswire-PRWeb/ -- T... |
| 30.05.2024 | Lymphoma Research Foundation Rebrands to Reflect Its Unifying Role Within the Lymphoma Community | New Lymphoma Research Foundation Logo (PRNewsfoto/Lymphoma Research Foundation)
Brand and visual identity demonstrate the Foundation's determination to support groundbreaking cancer research and commitment to improving the lives of the enti... |
| 02.05.2024 | Calquence combination improved PFS in 1L MCL | Calquence combination improved PFS in 1L MCL
Thu, May 02, 2024 08:00 CET Report this content
02 May 2024
Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival... |
| 25.01.2023 | Java Original Coffee Company to Support The Onco’Zine Brief Radio Broadcast and Podcast | The support from the Java Original Coffee Company helps us produce The Onco'Zine Brief and create awareness for difficult to treat cancers and topics including disparities in healthcare and access to cancer care as well as cancer prevention... |
| 26.01.2022 | BeiGene : Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA in Waldenström's Macroglobulinemia - Form 8-K | BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA
(zanubrutinib) in Waldenström's Macroglobulinemia
BRUKINSA received the China NMPA approval for the treatment of patients with relapsed or refractory
... |
| 21.01.2022 | BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenstrom's Macroglobulinemia | CAMBRIDGE, Mass., & BEIJING - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patien... |
| 16.12.2021 | BeiGene Announces Authorisation of BRUKINSA (zanubrutinib) from the United Kingdom's MHRA for the Treatment of Adults with Waldenstrom's Macroglobulinemia in Great Britain | BASEL, Switzerland & CAMBRIDGE, Mass. - BeiGene (NASDAQ: BGNE; HKEX: 06160) announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for BRUKINSA (zanubrutin... |
| 14.12.2021 | How Three People Living with Follicular Lymphoma Found Empowerment in Their Cancer Journey | (BPT) - Dealing with the complexities of a typically incurable blood cancer like follicular lymphoma can be challenging – but empowered communications between patients and their healthcare providers can help.
In My Blood is a new online res... |
| 24.11.2021 | BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenstrom's Macroglobulinemia | BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING - BeiGene (NASDAQ: BGNE; HKEX: 06160) announced that the European Commission (EC) approved BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenstrom's macroglobuline... |
| 20.09.2021 | Lymphoma Research Foundation Celebrates 15 Years of its Annual Lymphoma Research Ride | “It is truly remarkable to witness the idea my wife and I had 15 years ago for a community fundraiser transform into a national event,” said Bruce Cheson, MD, FACP, FAAAS, FASCO, Past Chair of LRF’s Scientific Advisory Board (SAB), and co-f... |
| 08.09.2021 | Survivor: Africa Winner, Humanitarian and Cancer Survivor Ethan Zohn Named an Official Ambassador for the Lymphoma Research Foundation | Ethan Zohn, Lymphoma Research Foundation Ambassador I am deeply proud to be an Ambassador for the Lymphoma Research Foundation and if I can motivate even one person to learn about the current research that is being done to help save lives f... |
| 11.08.2021 | Lymphoma Research Foundation to Honor Leaders in Lymphoma at the 2021 Annual Gala on Sept. 30 | "We are thrilled to recognize the significant impact our Gala’s honorees have made in advancing lymphoma research and improving patient care through their partnerships with the Foundation."
NEW YORK (PRWEB) August 11, 2021
The Lym... |
| 28.07.2021 | Laura Wallenstein Named Chief Philanthropy Officer for the Lymphoma Research Foundation | [Laura's] deep and abiding commitment to philanthropy will inform her work and have an incredible impact on our ability to fund the most promising lymphoma research.
NEW YORK (PRWEB) July 28, 2021
The Lymphoma Research Foundation (LRF) – th... |
| 07.07.2021 | Lymphoma Research Foundation Announces Sonali M. Smith, MD as Scientific Advisory Board Chair | Sonali M. Smith, MD of The University of Chicago assumes Chair of the Lymphoma Research Foundation's Scientific Advisory Board Under Dr. Smith’s leadership and with the collective guidance of the Scientific Advisory Board, I am confident th... |
| 26.04.2021 | FDA approves ADC Therapeutics antibody drug conjugate in B-cell lymphoma | The agency on Friday approved ADC drug loncastuximab tesirine for treating diffuse large B-cell lymphoma (DLBCL) in adults whose cancer has relapsed or has failed to respond to two or more earlier lines of systemic therapy. Lausanne, Switze... |
| 09.04.2021 | BEIGENE, LTD.
BeiGene : Launches BRUKINSA (Zanubrutinib) in Canada for Patients with Waldenstrom's Macroglobulinemia | MISSISSAUGA, Ontario - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the official launch of BRUKINSA (zanubrutin... |
| 08.04.2021 | Lymphoma Research Foundation Honors Michael E. Williams, MD with Mantle Cell Lymphoma Leadership Award | Dr. Williams' contributions to the LRF Mantle Cell Lymphoma Consortium have informed LRF’s education programming and resources for patients and led to the growth of the Foundation’s MCL research program.
NEW YORK (PRWEB) April 08, 2021
The ... |
| 08.04.2021 | CLINIGEN GROUP PLC
Clinigen : launches Managed Access Program with BeiGene for zanubrutinib | medicineaccess@clinigengroup.com.
8 April 2021
Clinigen launches Managed Access Program with BeiGene for zanubrutinib
Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical Products and Services company, has launched a Manage... |
| 08.04.2021 | BEIGENE, LTD.
BeiGene : Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström's Macroglobulinemia | BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the official launch of BRUKINSA® (zanubrutinib) in Canada for the ... |
| 31.03.2021 | Lymphoma Research Foundation Funds 29 Grants Investigating Lymphoma and Chronic Lymphocytic Leukemia, Introduces Expanded Research Program and Health Equity Initiative | Lymphoma Research Foundation's 2021 Research Grant Class / Investment “The Foundation is proud to not only remain committed to supporting lymphoma investigators but to expanding our research program at this critical time, accelerating scien... |
| 02.03.2021 | Exploring the patient-caregiver relationship: The story of a family's journey navigating a cancer diagnosis | (BPT) - When faced with a cancer diagnosis, life often changes drastically, with each person experiencing the impact differently. One change that can cause great uncertainty is an unexpected shift in relationships, especially with family or... |
| 04.12.2020 | Lymphoma Research Foundation Showcases Impressive Number of Researchers at 2020 American Society of Hematology Annual Meeting | The fact that we have nearly 90 percent of LRF’s Scientific Advisory Board members and more than 40 percent of LRF grantees involved in abstracts at this year’s ASH Annual Meeting speaks to the caliber of LRF’s world-class scientists and re... |
| 03.12.2020 | For People Living with Follicular Lymphoma, Routine Medical Check-ins are a Must—Here’s Why | (BPT) - The global COVID-19 pandemic is affecting nearly every part of daily life, and many people are choosing to skip or forgo their medical visits, screenings and tests. For people living with follicular lymphoma (FL), a typically incura... |
| 03.12.2020 | For People Living with Follicular Lymphoma, Routine Medical Check-ins are a Must—Here’s Why | (BPT) - The global COVID-19 pandemic is affecting nearly every part of daily life, and many people are choosing to skip or forgo their medical visits, screenings and tests. For people living with follicular lymphoma (FL), a typically incura... |
| 19.09.2017 | As care shifts from hospital to home, guarding against infection falls to families | Angela Cooper arrived home from work to discover her daughter’s temperature had spiked to 102 degrees — a sign that the teenager, who has cancer, had a potentially deadly bloodstream infection. As Cooper rushed her daughter to the hospital,... |
| 30.08.2017 | A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved | Reuters
Cancer cells are seen on a large screen connected to a microscope at the CeBit computer fair in Hanover, Germany, March, 6, 2012.
Advertisement
The US Food and Drug Administration (FDA) just approved a cutting-edge cancer therapy.
O... |
| 11.09.2014 | Focus on Lymphoma guides patients through treatment and beyond | Lymphoma is a type of blood cancer with over 60 subtypes. It is the fifth most common type of cancer (after breast, lung, colon and prostate) and has an unprecedented prevalence among young adults and adolescents -- it’s the most common for... |
| 21.02.2012 | Non-Hodgkin’s lymphoma drug company gets $15M venture backing | Ceptaris Pharmaceuticals in Malvern, Pennsylvania has received $7.5 million and will be given access to another $7.5 million if the NDA gets approved by U.S. regulators.
Its primary venture capital investors are Osage Ventures, Aperture Ven... |
| - | Non-Hodgkin’s lymphoma drug company gets $15M venture backing | A specialty pharmaceutical company has secured $15 million in venture debt backing for its topical gel drug to treat the early stages of mycosis fungoides, a type of non-Hodgkin’s lymphoma.
The investment will go toward operational expenses... |
| - | FDA approves ADC Therapeutics antibody drug conjugate in B-cell lymphoma | The most serious cases of lymphoma can be treated with a drug made by engineering a patient’s immune cells to target tumors. But CAR-T therapy doesn’t work in all cases. In securing its first FDA drug approval, ADC Therapeutics is now able ... |
| - | Accelerated FDA approval of Topotarget’s Beleodaq™ | To NASDAQ OMX Copenhagen A/SAnnouncement no. 17-14 / Copenhagen, July 3, 2014
— Accelerated Approval of BeleodaqTM for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma –
— Early Action before PDUFA date of ... |
